CytomX Therapeutics (CTMX) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for CytomX Therapeutics (CTMX) over the last 7 years, with Q3 2025 value amounting to -$0.09.
- CytomX Therapeutics' EPS (Weighted Average and Diluted) fell 22857.14% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.41, marking a year-over-year increase of 14117.65%. This contributed to the annual value of $0.38 for FY2024, which is 390000.0% up from last year.
- Latest data reveals that CytomX Therapeutics reported EPS (Weighted Average and Diluted) of -$0.09 as of Q3 2025, which was down 22857.14% from $0.27 recorded in Q1 2025.
- In the past 5 years, CytomX Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.27 during Q1 2025, and its lowest value of -$0.53 during Q4 2021.
- For the 5-year period, CytomX Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.15, with its median value being -$0.08 (2024).
- Examining YoY changes over the last 5 years, CytomX Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 220000.0% in 2024 and a maximum decrease of 30000.0% in 2024.
- CytomX Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.53 in 2021, then skyrocketed by 75.62% to -$0.13 in 2022, then surged by 107.69% to $0.01 in 2023, then soared by 2200.0% to $0.23 in 2024, then crashed by 139.13% to -$0.09 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.09 in Q3 2025, compared to $0.27 in Q1 2025 and $0.23 in Q4 2024.